

*Adapted from a scientific poster presented at  
the US Psychiatric and Mental Health Congress  
San Diego, CA, November 30th thru December 1st 2008*

# Cost-Effectiveness of Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Health Economic Analysis

*Ziad Nahas, M.D., Kit N. Simpson, Dr.PH, William M. McDonald, MD, Mary  
Jane Welch, DNP, APRN, BC, F. Andrew Kozel, MD, MSCR &  
Mark A. Demitrack, MD, for the TMS Therapy Study Group*

---

# Cost-Effectiveness of Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression: A Health Economic Analysis

---

Ziad Nahas, MD Department of Psychiatry, Medical University of South Carolina, Charleston, SC, Kit N. Simpson, DrPH, Department of Psychiatry, Medical University of South Carolina, Charleston, SC, William M. McDonald, MD, Department of Psychiatry, Emory University, Atlanta, GA, Mary Jane Welch, DNP, APRN, BC, Department of Psychiatry, Rush University, Chicago, IL, F. Andrew Kozel, MD, MSCR, Department of Psychiatry, University of Texas-Southwestern, Dallas, TX, and Mark A. Demitrack, MD, for the TMS Therapy Study Group, Neuronetics, Inc., Malvern, PA

---

## Abstract

**Background:** Transcranial magnetic stimulation (TMS) is a novel antidepressant shown to be effective and safe in patients who are treatment-resistant. Incremental cost-effectiveness and the direct cost burden of TMS are compared to sham treatment and to current standard of care.

**Methods:** Health care resource utilization was collected during a multi-center clinical trial of TMS monotherapy in patients with pharmacoresistant MDD (N=301). We used a decision analysis to stratify the acute outcomes and a severity-based risk of relapse Markov model to estimate the illness course over a full year of treatment follow up. We describe cost effectiveness of TMS by an incremental cost-effectiveness ratio (ICER) per quality adjusted life year (QALY) gained and on direct cost per patient basis, across a range of assumptions.

**Results:** Compared to sham treatment and at a cost of \$300 per treatment session, TMS has an ICER of \$34,999 per QALY. The ICER per QALY is reduced to \$6,667 with illness recovery and productivity gains. In open-label treatment, TMS provides a net cost savings of \$1,123 per QALY over current standard of care. Costs for caregiver burden and work loss result in further cost savings. The overall cost benefits of TMS are greatest in those patients with treatment resistance to fewer trials in the overall patient sample.

**Conclusions:** TMS is a cost-effective treatment for patients who have failed to receive sufficient benefit from initial antidepressant pharmacotherapy. When used in pharmacoresistant depression, significant cost savings may be expected relative to current standard of care pharmaceutical treatment.

---

## Introduction

In the United States, only 3.2 million of the 14 million patients with depression receive adequate pharmacotherapy (Kessler, 2003). Even in those who are treated, the success rate with pharmacological treatments is not high and short-term antidepressant drugs are only moderately effective when compared to placebo. The recently published results of the Sequenced Treatment Alternatives to Relieve Depression trial (STAR\*D) illustrate a pattern of diminishing clinical returns: each successive pharmacological treatment failure predicted a worse prognosis of a subsequent trial (Rush, 2006). The STAR\*D study showed that after three successive pharmacological treatment strategies the cumulative remission rate is at best only 67%.

Despite changes in treatment practice, the clinical impact of depression itself and of treatment resistance is growing. The World Health Organization (WHO) projects that by the year 2020, unipolar depression alone will be second in medical burden only to ischemic heart disease (Murray & Lopez, 1996). This somber prospect urges us to look for more effective and economically sound antidepressant treatments.

Non-pharmacological neuromodulation therapies (NMTs) have emerged in the last decade as potentially efficacious treatments for TRD. NMTs sub-convulsively modulate discrete networks with repetitive electrical stimulation. In contrast the therapeutic efficacy of electroconvulsive therapy (ECT) is dependent on the patient having an adequate major motor seizure. Transcranial magnetic stimulation (TMS) is a type of NMT whereby electrodeless stimulation is produced by a rapid oscillation in electrical energy which is converted to magnetic energy. If activated over the skull, anatomically and

functionally related brain regions are stimulated through cortical-subcortical neuronal circuits. Prefrontal TMS, repeated over several weeks, has a clinically significant acute antidepressant effect.

TMS has been shown to be safe and effective in the treatment of patients with major depression (O'Reardon et al, 2007; Janicak, et al, 2008; Avery, et al, 2008). Two reports (Kozel, et al, 2004; Knapp, et al, 2008) have already discussed the health economic impact of TMS in patients with pharmacoresistant depression. Both analyses were conducted using either historical estimates of TMS efficacy, or based on the results of a limited, fixed-dose treatment paradigm conducted in a small sample. Since those reports, we have published the results of the first large, multisite, randomized controlled study of TMS used as monotherapy in patients with pharmacoresistant depression. This clinical development program also included two open-label extension studies that provided information on acute efficacy and long-term durability of acute response to TMS.

Quality-adjusted year of life gained (QALY) quantifies the impact of a medical treatment both in terms of the quality and the quantity of life lived. There is no defined cost-effectiveness threshold value for the US, but an ICER below \$50,000 is generally considered highly cost-effective; it has been proposed that a de facto value for pharmaceuticals lies somewhere between \$50,000 and \$100,000 per QALY. The World Health Organization (WHO) suggests a limit for cost-effectiveness of three times a country's gross domestic product (GDP) per capita, which would set the upper limit at \$140,000 for the United States. However, acceptable

ICER values may vary with time and depend on the burden of the condition being treated, the size of the patient population affected, and health equity considerations. In this economic modeling study, we tested the incremental cost effectiveness ratio (ICER) for TMS compared to sham or compared to standard of care treatments. We hypothesized the incremental cost of TMS treatment would be lower than the societal willingness-to-pay threshold.

## Methods

### Clinical Development Program Overview

The overall clinical development program was composed of three separate clinical protocols that were related in temporal sequence to one another (Figure 1). A description of the study designs and outcomes for these protocols has been reported elsewhere.

### Motor Threshold Assessment, Treatment Location and TMS Treatment Parameters

All TMS sessions were delivered using the NeuroStar TMS Therapy System investigational device.

Treatment parameters were fixed per protocol and included stimulation at 120% of observed motor threshold applied at a pulse frequency of 10 pulses per second (cycle time: 4 seconds on and 26 seconds off) for a total of 3000 pulses per treatment session.

Motor threshold was determined using an iterated mathematical algorithm (MT Assist<sup>®</sup>) to ensure standardization across study sites.

Treatment location was by convention located at a site 5 cm anterior to the motor threshold location oriented on a line extending in a left superior oblique angle with a rotation point about the patient's nose.

During the acute efficacy phases of Study 101 and Study 102, TMS was administered 5 days per week for up to 6 weeks. During Study 103, TMS as an add-on rescue treatment was initiated at 2 days per week for the first 2 weeks, and then 5 days per week for the next 4 weeks.

## Decision Analysis Model Structure

In this study, we used a decision tree as the structural framework for organizing the efficacy outcome data for the six week acute treatment and the three week treatment taper phases. The tree segregated patients into groups who finished the six weeks of treatment in study 101 or 102 and those who did not finish. It then categorized patients into those who participated in the planned 3-week tapering phase and those who did not. Within each of these groups we characterized the distribution of patients using outcome criteria defined according to MADRS total score as follows: 1) 'MADRS 0', no depression (total score 0 to 9); 2) 'MADRS 1', mild depression, (total score 10 to 17); 3) 'MADRS 2', moderate depression, (total score 18 to 27); and 4) 'MADRS 3', severe depression; (total score > 27). At the end of the 9-week treatment period patients who completed the study period with an outcome in either of MADRS 0, MADRS 1 or MADRS 2, i.e., no depression, mild depression, or moderate depression, respectively, moved into a follow up Markov model which estimated the outcomes during the remaining year, based on the likelihood of progression by health state at the end of acute treatment. Patients who were classified as MADRS 3, severe depression at the end of acute treatment were moved into a separate Markov model where they were presumed to be treated with a new drug regimen combination consisting of a new antidepressant, a mood stabilizer, and an atypical antipsychotic. Note that the patients in the MADRS 3 group can be presumed to have demonstrated failure to benefit from at least two prior antidepressant treatments (i.e., ATHF-verified failure of antidepressant pharmacotherapy prior to study entry, and subsequent prospectively demonstrated failure to benefit from TMS during the TMS study itself). Therefore, the estimates of the potential efficacy of future antidepressant treatment for the MADRS 3 group in the Markov model were based on the results reported for Levels 3 and 4 in the STAR\*D Study, i.e., the groups in that study who had also failed to benefit from at least two antidepressant treatment exposures. The decision analysis model was programmed in Excel (Microsoft Corp., Seattle, WA).

## Data Analysis Methods and Model Parameters

An analytical economic dataset and the specific model parameters specifying acute treatment outcome and severity-specific relapse rates estimated over one year of follow up that were used in the decision analysis model were derived from the actual raw clinical efficacy outcome data from the Neuronetics Studies 101, 102 and 103.

Health resource utilization was obtained for all patients in the clinical trial at entry into Study 101 and again at their point of exit from Study 103. This utilization information was obtained using a self-report questionnaire designed specifically for use in this study. The information covered three major domains of information (Work Productivity/Work Loss [9 items], Health Care Utilization and Cost [18 items], and Caregiver Support [4 items]). These costs were applied to both treatment arms in the model (for the Neuronetics study and for the STAR\*D trial outcomes).

The overall clinical and health outcomes information was then combined with standard cost weights drawn from large national databases (H-CUP 2004; <http://www.hcup-us.ahrq.gov>). Detailed cost weights were estimated for subgroups of patients

**Figure 1. NeuroStar Clinical Development Program**



<sup>1</sup> O'Reardon, et al, *Biol Psychiatry*, 2007

<sup>2</sup> Janicak, et al, *J Clin Psychiatry*, 2008

<sup>3</sup> Avery, et al, *J Clin Psychiatry*, 2008

with similar clinical severity, where the clinical severity was defined by the MADRS criteria described above in the Decision Analysis Model. These subgroups were used to define the outcomes for patients at the end of the acute efficacy treatment in the respective clinical trial (i.e., either the Neuronetics studies or the STAR\*D study), and to link the trial results to cost and quality of life weights reported in the literature. The results of the analysis of the clinical trial data were linked to health state-specific relapse rates estimated over a one year period following their acute treatment, using the actual follow-up data from Study 103 to estimate this one year interval.

The perspective for costing in the model is that of the US health system using 2007 standard cost estimates based on mean study reported resource uses. As noted above, the mean utilization values estimated from the study data were combined with unit cost weights derived from the analysis of a large sample of 2004 Medicaid billing data for patients with depression (South Caro-

2004 mean costs (not charges) were then inflated to equivalent 2007 cost weights using the medical care consumer price index over that interval of time. In the model outputs reported here that include the cost of lost productivity, we have assumed 2 hours of lost time per treatment received. As a Base Case, each TMS session was estimated to cost the healthcare system US\$300. The incremental cost effectiveness ratio (I-CER) for all reported model estimates was calculated as the difference in the one-year cost of treating 100 patients with TMS minus the difference in the cost expected for treating 100 patients in the control group (sham TMS or pharmacotherapy, depending upon the specific model being considered), divided by the difference in the QALYs produced by the two treatments over one year. The model parameters and cost weights are provided in Table 1. The costs of the various pharmacotherapy regimens considered for the models are summarized in Tables 1 & 2. Final analyses utilized costs from antidepressant treatment regimen 2 for the re-treatment part of the model.

**Table 1. Model Parameters and Cost Weights**

Parameter/Variables	Base Model Value	Range for Sensitivity Analysis	Data Sources
MADRS 0 Utility weight	.83	.80 - .86	Revicki, 1995; NICE 2006
MADRS 1 Utility weight	.73	.70 - .76	Revicki, 1995 NICE 2006
MADRS 2 Utility weight	.63	.60 - .66	Revicki, 1995 NICE 2006
MADRS 3 Utility weight	.30	.27 - .33	Revicki, 1995 NICE 2006
In Hospital failure	.09	.06 - .12	Kamlet, 1995 NICE 2006
<b>Decision Tree Model:</b>			
TMS treatment (Base case)	US\$300	±10%	Neuronetics studies
MADRS 0; Medical care/day	US\$2.16	±10%	Neuronetics studies
MADRS 1 Medical care/day	US\$2.16	±10%	Neuronetics studies
MADRS 2 Medical care/day	US\$3.01	±10%	Neuronetics studies
MADRS 3 Medical care/day	US\$3.94	±10%	Neuronetics studies
MADRS 0 Productivity/day	US\$33.37	±10%	Neuronetics studies
MADRS 1 Productivity/day	US\$43.80	±10%	Neuronetics studies
MADRS 2 Productivity/day	US\$99.40	±10%	Neuronetics studies
MADRS 3 Productivity/day	US\$128.59	±10%	Neuronetics studies
Median hourly wage for patient during treatment	US\$12.00	±10%	Neuronetics studies
Lost wages per treatment	US\$509.04	±10%	Neuronetics studies
<b>Markov Model:</b>			
Hospital cost/day	US\$880	±10%	Medicaid 2004
ER cost/visit	US\$426	±10%	Medicaid 2004
MD office visit	US\$129		Medicaid 2004
Antidepressant maintenance drug cost /day	US\$1.53	±10%	Red Book 2006
Follow up drug cost to treat failure/day	US\$2.20	±10%	Red Book 2006
Retreatment cost for patients in severe health state	US\$22.63	See separate table 3	Red Book 2006
Marginal cost of hospital care for suicide	US\$852	US\$40,000	Medicaid 2004
24 week failure	TMS	Sham	
MADRS 0	30%	33%	Study 103
MADRS 1	23%	50%	Study 103
MADRS 2	33%	50%	Study 103
MADRS 3	33%	50%	Study 103
Efficacy of pharmaceutical treatment regimens used for MADRS 3 patients	14%	14%	Rush et al, 2006

**Table 2. Model Cost of Pharmaceutical Treatment Regimens for Patients with Severe Depression**

Drug Type	Drug Name	Daily Dose	Cost per Day*	Cost per Week
<b>Regimen 1</b>				
Antidepressant	Fluoxetine	20mg	2.66	
Mood stabilizer	Carbamazepine	100mg	0.43	
Atypical Antipsychotic	Olanzapine	5mg	11.76	
Total Cost of Regimen			[14.85]	[103.95]
<b>Regimen 2</b>				
Antidepressant	Sertraline	150mg	4.21	
Mood stabilizer	Valproic acid	1500mg	6.87	
Atypical Antipsychotic	Aripiprazole	10mg	11.55	
Total Cost of Regimen			[22.63]	[158.41]
<b>Regimen 3</b>				
Antidepressant	Venlafaxine	37.5mg	2.07	
Mood stabilizer	Lamotrigine	200mg	3.83	
Atypical Antipsychotic	Olanzapine	20mg	23.50	
Total Cost of Regimen			[29.40]	[205.80]

\* AWP from 2006 Red Book

The model first estimated outcomes for TMS compared to Sham treatment using the Study 101 overall population data. As the experience in a blinded randomized controlled trial and a comparison to sham are not fully reflective of the expected clinical outcomes with TMS in ordinary clinical practice where other actual treatments options would be considered, we performed three additional model estimates to place these results in context, comparing these model estimates to best estimates of outcomes and costs of pharmacotherapy treatment as usual, using the published STAR\*D outcomes for this comparison. These three additional model estimates included:

1. a comparison of one year outcomes for the overall patient population treated with TMS in the open-label Study 102 data versus a synthetic comparison group of clinical outcomes observed in the published results from the STAR\*D trial for Levels 2 and 3 combined in that study;
2. an examination of the impact of prior antidepressant treatment resistance by performing a comparison of the Study 101 active TMS vs Sham using only data from patients who had failed one adequate prior antidepressant treatment in their current episode (ATHF=1). These patients had a median of 4 antidepressant attempts; and finally;
3. a comparison of the open-label Study 102 clinical outcomes restricted to those patients within the overall study population who experienced one adequate prior antidepressant treatment in their current illness episode (ATHF=1) vs. a STAR\*D synthetic comparison group restricted to the Level 2 outcomes only.

We tested each model estimate's sensitivity to variations in the assumptions, cost weights and quality of life adjustments used for each estimate. Specifically, we tested the impact of two key model parameters alone and in combination: 1) either excluding or including indirect costs in the model, and 2) varying the estimated cost of a suicide attempt. Clinical out-

comes in the STAR\*D comparison datasets are reported using the Hamilton Depression Rating Scale (HDRS). We used the information provided on the IDS/QIDS website (<http://www.ids-qids.org/index2.html#table4>) to establish clinically equivalent rating comparisons of the HDRS data to the MADRS scores used in the Neuronetics dataset. All statistical analyses were performed with SAS version 8.1 (Cary, North Carolina, USA).

## Results

### Study Population

Demographic and clinical features of the overall study population treated with the NeuroStar TMS System are shown in Table 3.

### Decision Analysis Model Outcomes


Results of the decision analysis for the acute treatment phase in both active TMS (N=155) and sham TMS (N=146) randomized groups in Study 101 are shown in Figure 2a. Results for the decision analysis for the acute treatment phase of all patients (N=158) in the open-label Study 102 is shown in Figure 2b.

A similar decision analysis model was applied to the outcomes from the STAR\*D trial to establish a comparison benchmark for pharmaceutical treatment of patients who had failed initial antidepressant pharmacotherapy. The STAR\*D results for Levels 2 and 3 combined were used as a comparison for the overall population in the Neuronetics studies, while the results for the Level 2 STAR\*D group alone were used as a comparison for the subgroup of patients in the Neuronetics studies who experienced only one adequate prior antidepressant treatment in their current illness episode (ATHF=1). Results of this analysis are shown in Figure 2c.

**Table 3. Demographic and Clinical Features of the NeuroStar Study Population**


	Active TMS (n=155)	Sham TMS (n=146)	P-Value
<b>Demographic Variables</b>			
n(%) females	86(55.5)	74(50.7)	.421
Age (years ±SD)	47.9±11.0	48.7±10.6	.509
Ethnic Origin, n(%)			
Caucasian	146 (94.2)	131(89.7)	
Other	9(5.8)	15(10.3)	.201
<b>Employment Status, n(%)</b>			
Full Time	58(35.6)	45(28.3)	
Part Time	27(16.6)	31(19.5)	
Unemployed	78(47.9)	83(52.2)	
Receiving Disability Compensation	28(32.9)	31(34.1)	
<b>Disease History</b>			
Recurrent Illness Course (%)	149(95.5)	136(93.8)	.611
Duration of current episode in months, Mean(SD)	13.6(9.9)	13.2(9.5)	.728
n(%) of population with current episode ≥2 years	36(23.2)	23(15.8)	.112
Prior Antidepressant Treatment			
Number of antidepressant treatment attempts in current illness episode (mean, SD)	5.5 (3.4)	5.4 (3.6)	.774
Number of dose/duration adequate antidepressant treatments in current episode (mean, SD)	1.6 (0.9)	1.6 (0.8)	.905
<b>Baseline Symptom Scores</b>			
MADRS total score (SD)	32.8(6.0)	33.9(5.7)	.036
HAMD17 total score(SD)	22.6(3.3)	22.9(3.5)	.508
HAMD24 total score(SD)	30.1(5.0)	30.5(4.9)	.568
CGI –Severity (SD)	4.7(0.6)	4.7(0.7)	.197
IDS-SR total score(SD)	42(9.4)	43.4(9.9)	.197

**Figure 2a. Decision Tree Outcomes for Acute Phase (six-week) Treatment in Study 101: Overall Study Population**




**NOTES:** MADRS 0 = total score 0-9, MADRS 1 = total score 10-17, MADRS 2 = total score 18-27, MADRS 3 = total score > 27.

**Figure 2b. Decision Tree Outcomes for Acute Phase (six-week) Treatment in Study 102: Overall Study Population**



NOTES: MADRS 0 = total score 0-9, MADRS 1 = total score 10-17, MADRS 2 = total score 18-27, MADRS 3 = total score > 27.

**Figure 2c. Decision Tree Outcomes for Acute Phase Pharmacotherapy Treatment**



NOTES: Data adapted from the published results of the STAR\*D study. MADRS 0 = total score 0-9, MADRS 1 = total score 10-17, MADRS 2 = total score 18-27, MADRS 3 = total score > 27.

**Results**

**Incremental Cost Effectiveness Ratios (ICERs) or Cost Savings**

Data for the incremental cost effectiveness ratios (ICERs) or the economically dominant model estimates of cost savings for the various decision analysis models for the Base Case alone are summarized in Table 4 for both the randomized controlled trial Study 101 and the open-label Study 102.

**Cost Savings per Year of Treatment: Summary of Break-Even Time Points**

A comprehensive summary of the cost savings (or cost increases) per year of treatment with the NeuroStar TMS System is shown in Figure 3. Outcomes vary depending on the assumed treatment cost. In this display, we show the results for the Open-Label Study 102 with the similar open-label study outcomes for the STAR\*D trial. The results are shown for the subgroup of patients at the earliest levels of treatment resistance in both studies (i.e., those patients in treated with NeuroStar who had failed to receive benefit from one antidepressant treatment at minimal effective dose and duration in current episode compared to the STAR\*D Level 2 outcomes).


We also estimated the time to break-even cost in this model, for the Base Case model (i.e., an estimated TMS per treatment session cost of \$300). In this analysis, the mean cost for a TMS patient would be completely offset at 28 weeks, when compared to the expenditure flow expected for patients from Level 2 of the STAR\*D trial over 12 months of treatment.

**Table 4. Incremental Cost Effectiveness Ratios (incremental cost per QALY gained) or Dominant Cost Savings (per treated patient per year) for the Various Economic Models Examined: Base Case Cost**

Model Structure	Study Population	Incremental Cost Effectiveness Ratio (ICER) or Dominant [Cost Savings]	
		With Productivity Costs Included in the Model	Without Productivity Costs Included in the Model
Acute TMS vs Sham (Randomized, Controlled Trial Study 101)	Overall (N=301)	US\$6,667	US\$34,999
	ATHF = 1 (N=164)	[US\$88]	US\$29,556
Acute TMS (Open-Label Study 102) vs Pharmacotherapy Treatment as Usual (STAR*D Study)	Overall (N=301)	[US\$7,621]	[US\$1,123]
	ATHF = 1 (N=164)	[US\$10,516]	[US\$2,406]

NOTES: Costs in [brackets] represent economically dominant model estimates for TMS, and are reported as cost savings per treated patient per year. All other costs represent incremental cost

Figure 3. Savings (Costs) Per Patient Per Year Treated with TMS (Model: Open-Label Study 102, ATHF 1 Study Population Only N=164) With and Without Productivity Gains Included in Model



### Conclusions

- TMS is a safe and effective treatment option for patients who have failed to receive benefit from antidepressant pharmacotherapy
- In patients with pharmacoresistant major depression, significant cost savings may be expected relative to current standard of care pharmacotherapy when used at the earliest stages of treatment resistance
  - The most conservative estimate of the incremental cost-effectiveness ratio (ICER) for TMS is \$34,999 per QALY, well below the most stringent willingness-to-pay threshold for a new treatment
  - Treatment with open-label TMS shows an actual cost savings of \$10,516 per patient per year when productivity gains are included, and \$2,406 with health gains only included in the model estimates
- The mean cost for a patient receiving an acute treatment course of TMS would be offset at 28 weeks (“break-even”) when compared to the expenditure for pharmacotherapy over 12 months of treatment

### References

Avery DH, Isenberg KE, Sampson S, Janicak PG, Lisanby SH, Maixner DF, Loo C, Thase ME, Demitrack MA, George MS (2008). Transcranial magnetic stimulation in the acute treatment of major depression: Clinical response in an open-label extension trial. *J Clin Psychiatry* 69:441-451.

## References Continued...

- Janicak P, O'Reardon J, Sampson S, Husain MM, Lisanby SH, Rado JT, Heart KL, Demitrack MA (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: A comprehensive summary of safety experience from acute exposure, extended exposure and reintroduction treatment. *J Clin Psychiatry* 69:222-232.
- Kessler, RC, Berglund, P, Demler, O, Jin, R, Koretz, D, Merikangas, KR, Rush, AJ, Walters, EE, Wang, PS, (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). *JAMA* 289 (23), 3095.
- Kozel, FA, George, MS, Simpson, K. N. (2004) Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. *CNS Spectr* 9 (6), 476.
- Knapp, M, Romeo, R, Mogg, A, Eranti, S, Pluck, G, Purvis, R, Brown, RG, Howard, R, Philpot, M, Rothwell, J, Edwards, D, McLoughlin, D. M. (2008) Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomized controlled trial. *J Affect Disord* 109 (3), 273.
- Murray CJ, Lopez AD, eds. *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk factors in 1990 and Projected to 2020*. Cambridge, MA: Harvard University Press; 1996.
- Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR\*D report. *American Journal of Psychiatry* 163:1905-1917.
- O'Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, McDonald WM, Avery DH, Fitzgerald PB, Loo C, Demitrack MA, George MS, Sackeim HA (2007). Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. *Biological Psychiatry* 62:1208-1216.

---

## The TMS Therapy Study Group

- \* Aaronson, S (Sheppard Pratt Health System, Baltimore, MD)
- \* Avery, D (University of Washington, Seattle, WA)
- \* Canterbury, R (University of Virginia, Charlottesville, VA)
- \* Daskalakis, ZJ (Centre for Addiction and Mental Health, Toronto, Canada)
- \*\* Demitrack, MA (Neuronetics, Inc., Malvern, PA)
- \* Fitzgerald, P (The Alfred Hospital, Melbourne, Australia)
- \* Gilmer, W, \* (Northwestern University, Chicago, IL)
- \* Gutierrez, R (PsyCare, Inc., Poway, CA)
- \* Husain, M (UT Southwestern, Dallas, TX)
- \* Isenberg, K (Washington University, St. Louis, MO)
- \* Janicak, P (Rush University, Chicago, IL)
- \* Krystal, A (Duke University, Durham, NC)
- \*\* George, M (Medical University of South Carolina, Charleston, SC)
- \* Lisanby, S (Columbia University, New York, NY)
- \* Loo, C (The Black Dog Institute, Sydney, Australia)
- \* Maixner, D (University of Michigan, Ann Arbor, MI)
- \* Marangell, L (Baylor College of Medicine, Houston, TX)
- \* McDonald, W (Emory University, Atlanta, GA)
- \* Nahas, Z (Medical University of South Carolina, Charleston, SC)
- \* O'Reardon, JP (University of Pennsylvania, Philadelphia, PA)
- \* Richelson, E (Mayo Clinic, Jacksonville, FL)
- \* Rosenquist, P (Wake Forest University, Winston-Salem, NC)
- \*\* Sackeim, H (Columbia University, New York, NY)
- \* Sampson, S (Mayo Clinic, Rochester, MN)
- \*\* Schatzberg, AF (Stanford University, Palo Alto, CA)
- \* Solvason, HB (Stanford University, Palo Alto, CA)

\* Principal Investigators, \*\* Steering Committee Members